{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004239703084160.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.3899/jrheum.130901"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.3899/jrheum.130901"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Longterm Retention Rate and Risk Factor for Discontinuation Due to Insufficient Efficacy and Adverse Events in Japanese Patients with Rheumatoid Arthritis Receiving Etanercept Therapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Objective.</jats:title><jats:p>Assessing retention rate and risk factor for drug discontinuation is important for drug evaluation. We examined a 3-year retention rate and the risk factor for discontinuation due to insufficient efficacy (IE) and adverse events (AE) in Japanese patients with rheumatoid arthritis (RA) who are receiving etanercept (ETN).</jats:p></jats:sec><jats:sec><jats:title>Methods.</jats:title><jats:p>Data were collected from 588 patients treated with ETN as a first biologic from the Tsurumai Biologics Communication Registry. Baseline characteristics for the incidence of both IE and AE were analyzed using the Cox proportional-hazards regression model. Patients were divided into groups based on age and concomitant methotrexate (MTX). Drug retention rates were calculated using the Kaplan-Meier method and compared among groups using the log-rank test.</jats:p></jats:sec><jats:sec><jats:title>Results.</jats:title><jats:p>ETN monotherapy without concomitant MTX [MTX(–)] was significantly related to a higher incidence of discontinuation due to IE [hazard ratio (HR) = 2.226, 95% CI 1.363–3.634]. Older age and MTX(–) were significantly related to a higher incidence of discontinuation due to AE [HR = 1.040, 1.746, 95% CI 1.020–1.060, 1.103–2.763, respectively]. The MTX(–)/≥ 65 years group had the lowest retention rate (p < 0.001). The discontinuation rate due to IE was lower in the MTX(+)/< 65 years group compared to < 65 years/MTX(–), ≥ 65 years/MTX(–) group (p = 0.006, p < 0.001, respectively). The discontinuation rate due to AE was highest in the MTX(–)/≥ 65 years group (p < 0.001).</jats:p></jats:sec><jats:sec><jats:title>Conclusion.</jats:title><jats:p>Our findings suggest that the risk of discontinuation due to IE was high in the patients who did not use concomitant MTX and that the risk of discontinuation due to AE was high in elderly patients who did not use concomitant MTX.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004239703084034","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Matsubara"}]},{"@id":"https://cir.nii.ac.jp/crid/1420845751153989504","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70378032"},{"@type":"NRID","@value":"1000070378032"},{"@type":"NRID","@value":"9000314781759"},{"@type":"NRID","@value":"9000003217237"},{"@type":"NRID","@value":"9000255992159"},{"@type":"NRID","@value":"9000005802279"},{"@type":"NRID","@value":"9000241669972"},{"@type":"NRID","@value":"9000398266817"},{"@type":"NRID","@value":"9000327450602"},{"@type":"NRID","@value":"9000304603787"},{"@type":"NRID","@value":"9000356478267"},{"@type":"NRID","@value":"9000361694176"},{"@type":"NRID","@value":"9000325461019"},{"@type":"NRID","@value":"9000249497367"},{"@type":"NRID","@value":"9000290363281"},{"@type":"NRID","@value":"9000403417879"},{"@type":"NRID","@value":"9000404129855"},{"@type":"NRID","@value":"9000002239075"},{"@type":"NRID","@value":"9000398406051"},{"@type":"NRID","@value":"9000321621051"},{"@type":"NRID","@value":"9000290815769"},{"@type":"NRID","@value":"9000336385024"},{"@type":"NRID","@value":"9000334420965"},{"@type":"NRID","@value":"9000398616461"},{"@type":"NRID","@value":"9000389566774"}],"foaf:name":[{"@value":"Toshihisa Kojima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084174","@type":"Researcher","foaf:name":[{"@value":"Atsushi Kaneko"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084162","@type":"Researcher","foaf:name":[{"@value":"Yuji Hirano"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084177","@type":"Researcher","foaf:name":[{"@value":"Hisato Ishikawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084170","@type":"Researcher","foaf:name":[{"@value":"Yousuke Hattori"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084032","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Miyake"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084160","@type":"Researcher","foaf:name":[{"@value":"Takeshi Oguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084167","@type":"Researcher","foaf:name":[{"@value":"Hideki Takagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084176","@type":"Researcher","foaf:name":[{"@value":"Yuichiro Yabe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084173","@type":"Researcher","foaf:name":[{"@value":"Takefumi Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084168","@type":"Researcher","foaf:name":[{"@value":"Takayasu Ito"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084166","@type":"Researcher","foaf:name":[{"@value":"Naoki Fukaya"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084033","@type":"Researcher","foaf:name":[{"@value":"Yasuhide Kanayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084163","@type":"Researcher","foaf:name":[{"@value":"Tomone Shioura"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084171","@type":"Researcher","foaf:name":[{"@value":"Masatoshi Hayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084036","@type":"Researcher","foaf:name":[{"@value":"Takayoshi Fujibayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084164","@type":"Researcher","foaf:name":[{"@value":"Nobunori Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084172","@type":"Researcher","foaf:name":[{"@value":"Koji Funahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084035","@type":"Researcher","foaf:name":[{"@value":"Daizo Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084165","@type":"Researcher","foaf:name":[{"@value":"Masahiro Hanabayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084161","@type":"Researcher","foaf:name":[{"@value":"Kenya Terabe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239703084169","@type":"Researcher","foaf:name":[{"@value":"Naoki Ishiguro"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0315162X"},{"@type":"EISSN","@value":"14992752"}],"prism:publicationName":[{"@value":"The Journal of Rheumatology"}],"dc:publisher":[{"@value":"The Journal of Rheumatology"}],"prism:publicationDate":"2014-07-15","prism:volume":"41","prism:number":"8","prism:startingPage":"1583","prism:endingPage":"1589"},"reviewed":"false","url":[{"@id":"https://syndication.highwire.org/content/doi/10.3899/jrheum.130901"}],"createdAt":"2014-07-16","modifiedAt":"2024-05-30","project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782305346688","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"26462290"},{"@type":"JGN","@value":"JP26462290"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26462290/"}],"notation":[{"@language":"ja","@value":"関節リウマチに対する抗RANKL抗体と炎症性サイトカイン阻害薬併用療法の治療効果"},{"@language":"en","@value":"Inhibitory effects of combination therapy of denosumab, anti-RANKL antibody, and biological DMARD on bone and cartilage destruction in patients with rheumatoid arthritis"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050025031478204160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis"},{"@value":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1050287297263335552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231302072576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239703172352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146598919552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate"}]},{"@id":"https://cir.nii.ac.jp/crid/1360282588975731968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285704848155520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567184206882944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094984288896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656994676480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568494351872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"TNF‐α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044926309120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Predictors of infection in rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046065408768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519118382080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519322365184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469056841088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370427129600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844166111488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318423945216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320749625600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793984330368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794519857280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795953743232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serious infections during anti-TNFα treatment in rheumatoid arthritis patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270218733312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment continuation in patients receiving biological agents or conventional DMARD therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270666195968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long term safety of etanercept in elderly subjects with rheumatic diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282763049453952","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"関節リウマチにおけるエタネルセプト 25 mg/週の長期臨床効果，治療継続率，安全性の検討"},{"@language":"en","@value":"Long-Term Clinical Efficacy, Retention Rate, and Safety of 25 mg/week Etanercept in Patients with Rheumatoid Arthritis"},{"@language":"ja-Kana","@value":"カンセツ リウマチ ニ オケル エタネルセプト 25mg/シュウ ノ チョウキ リンショウ コウカ,チリョウ ケイゾクリツ,アンゼンセイ ノ ケントウ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.3899/jrheum.130901"},{"@type":"KAKEN","@value":"PRODUCT-15268874"},{"@type":"OPENAIRE","@value":"doi_dedup___::bdb39cc29e4c16b211bfad42e02a3275"},{"@type":"CROSSREF","@value":"10.1016/j.clinthera.2016.03.022_references_DOI_QVCbW5ECmXKZZmrypjuDivUIUqF"},{"@type":"CROSSREF","@value":"10.4264/numa.77.4_229_references_DOI_QVCbW5ECmXKZZmrypjuDivUIUqF"},{"@type":"CROSSREF","@value":"10.1080/14397595.2018.1525019_references_DOI_QVCbW5ECmXKZZmrypjuDivUIUqF"},{"@type":"CROSSREF","@value":"10.3899/jrheum.151006_references_DOI_QVCbW5ECmXKZZmrypjuDivUIUqF"}]}